STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
Public ClinicalTrials.gov record NCT03548935. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Effect and Safety of Semaglutide 2.4 mg Once-weekly in Subjects With Overweight or Obesity
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will look at the change in participants' body weight from the start to the end of the study. The weight loss in participants taking semaglutide (a new medicine) will be compared to the weight loss of participants taking "dummy" medicine. In addition to taking the medicine, participants will have talks with study staff about healthy food choices, how to be more physically active and what you can do to lose weight. Participants will either get semaglutide or "dummy" medicine - which treatment participants get, is decided by chance. Participants will need to take 1 injection once a week. The study medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm. The study has two phases: A main phase and an extension phase.The main phase will last for about 1.5 years. Participants will have 15 clinic visits and 10 phone calls with the study doctor. Extension phase: Approximately 300 participants will continue in the extension phase in the following countries only: Canada, Germany, the UK and selected sites in the US and Japan. These participants will be in the study for about 2.5 years.They will not receive treatment, but will attend another 5 follow-up visits with the study doctor.
Study identification
- NCT ID
- NCT03548935
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,961 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 4, 2018 (Actual)
- Primary completion
- Mar 30, 2020 (Actual)
- Completion
- Mar 5, 2021 (Actual)
- Last update posted
- Nov 19, 2021
2018 – 2021
United States locations
- U.S. sites
- 39
- U.S. states
- 23
- U.S. cities
- 35
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novo Nordisk Investigational Site | Anniston | Alabama | 36207 | — |
| Novo Nordisk Investigational Site | Anaheim | California | 92801 | — |
| Novo Nordisk Investigational Site | Lomita | California | 90717 | — |
| Novo Nordisk Investigational Site | Spring Valley | California | 91978 | — |
| Novo Nordisk Investigational Site | Aurora | Colorado | 80045 | — |
| Novo Nordisk Investigational Site | Waterbury | Connecticut | 06708 | — |
| Novo Nordisk Investigational Site | Chiefland | Florida | 32626 | — |
| Novo Nordisk Investigational Site | Crystal River | Florida | 34429 | — |
| Novo Nordisk Investigational Site | Jacksonville | Florida | 32205 | — |
| Novo Nordisk Investigational Site | Jacksonville | Florida | 32216 | — |
| Novo Nordisk Investigational Site | Ocala | Florida | 34470 | — |
| Novo Nordisk Investigational Site | Panama City | Florida | 32401 | — |
| Novo Nordisk Investigational Site | Plantation | Florida | 33324 | — |
| Novo Nordisk Investigational Site | Ponte Vedra | Florida | 32081 | — |
| Novo Nordisk Investigational Site | Roswell | Georgia | 30076 | — |
| Novo Nordisk Investigational Site | Chicago | Illinois | 60607 | — |
| Novo Nordisk Investigational Site | Chicago | Illinois | 60611 | — |
| Novo Nordisk Investigational Site | Indianapolis | Indiana | 46260 | — |
| Novo Nordisk Investigational Site | Topeka | Kansas | 66606 | — |
| Novo Nordisk Investigational Site | Louisville | Kentucky | 40213 | — |
| Novo Nordisk Investigational Site | Buckley | Michigan | 49620 | — |
| Novo Nordisk Investigational Site | City of Saint Peters | Missouri | 63303 | — |
| Novo Nordisk Investigational Site | Butte | Montana | 59701 | — |
| Novo Nordisk Investigational Site | Omaha | Nebraska | 68105 | — |
| Novo Nordisk Investigational Site | Rochester | New York | 14609 | — |
| Novo Nordisk Investigational Site | Salisbury | North Carolina | 28144 | — |
| Novo Nordisk Investigational Site | Wilmington | North Carolina | 28401 | — |
| Novo Nordisk Investigational Site | West Reading | Pennsylvania | 19611 | — |
| Novo Nordisk Investigational Site | Charleston | South Carolina | 29425 | — |
| Novo Nordisk Investigational Site | Simpsonville | South Carolina | 29681 | — |
| Novo Nordisk Investigational Site | Nashville | Tennessee | 37212-1150 | — |
| Novo Nordisk Investigational Site | Austin | Texas | 78749 | — |
| Novo Nordisk Investigational Site | Dallas | Texas | 75226 | — |
| Novo Nordisk Investigational Site | Dallas | Texas | 75230 | — |
| Novo Nordisk Investigational Site | Dallas | Texas | 75234 | — |
| Novo Nordisk Investigational Site | Round Rock | Texas | 78681 | — |
| Novo Nordisk Investigational Site | Bountiful | Utah | 84010 | — |
| Novo Nordisk Investigational Site | Richmond | Virginia | 23294 | — |
| Novo Nordisk Investigational Site | Renton | Washington | 98057 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 89 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03548935, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 19, 2021 · Synced Nov 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03548935 live on ClinicalTrials.gov.